The Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations

At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular mar...

Descripción completa

Detalles Bibliográficos
Autor principal: Persinger, Rasheda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2021
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087227/
https://www.ncbi.nlm.nih.gov/pubmed/34084579
http://dx.doi.org/10.6004/jadpro.2021.12.3.17
Descripción
Sumario:At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET, and KRAS mutations, and described the different testing modalities for molecular markers.

Ejemplares similares